| 7.02 0.21 (3.08%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.14 | 1-year : | 49.87 |
| Resists | First : | 28.37 | Second : | 42.7 |
| Pivot price | 6.03  |
|||
| Supports | First : | 5.2 | Second : | 4.33 |
| MAs | MA(5) : | 6.1 |
MA(20) : | 11.38 |
| MA(100) : | 26.35 |
MA(250) : | 0 | |
| MACD | MACD : | -7 |
Signal : | -7.8 |
| %K %D | K(14,3) : | 58.6 |
D(3) : | 29.5 |
| RSI | RSI(14): 27 |
|||
| 52-week | High : | 55.88 | Low : | 5.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KRRO ] has closed Bollinger Bands are 88.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.25 - 7.28 | 7.28 - 7.31 |
| Low: | 6.66 - 6.69 | 6.69 - 6.72 |
| Close: | 6.97 - 7.02 | 7.02 - 7.08 |
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Sun, 16 Nov 2025
StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia - Genetic Engineering and Biotechnology News
Thu, 13 Nov 2025
Korro Bio stock crashes as it cuts 34% of workforce due to clinical trial fail - The Business Journals
Thu, 13 Nov 2025
Korro Bio’s Downslide: Crisis or Opportunity? - timothysykes.com
Thu, 13 Nov 2025
Korro Bio nominates KRRO-121 as development candidate - BioWorld MedTech
Thu, 13 Nov 2025
Korro lays off 34% of staff as lead drug disappoints and Novo Nordisk pauses pact - Fierce Biotech
Thu, 13 Nov 2025
Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing - BioPharma Dive
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 5.78e+006 (%) |
| Held by Institutions | 6.1 (%) |
| Shares Short | 1,060 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.961e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 764.8 % |
| Return on Equity (ttm) | -29.2 % |
| Qtrly Rev. Growth | 7.37e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -28.72 |
| EBITDA (p.s.) | 20814.5 |
| Qtrly Earnings Growth | -9.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -68 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.25 |
| Price to Cash Flow | 1.47 |
| Dividend | 0 |
| Forward Dividend | 1.44e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|